Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

AIM: To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy. METHODS: In this prospective, adaptive, phase-2/3, open-label study (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sudeep, Biswas, Ghanashyam, Babu, Suresh, Maksud, Tanveer M., Lakshmaiah, Kuntegowdennahalli C., Patel, Jayanti G., Raja, Gopal, Boya, Rakesh R., Patil, Pramod, Choudhury, Kakali, Bondarde, Shailesh A., Neve, Rakesh S., Bhat, Guruprasad, Mamillapalli, Gopichand, Patel, Apurva A., Patel, Piyush, Joshi, Nisarg, Bajaj, Vinay, Khan, Mujtaba A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503662/
https://www.ncbi.nlm.nih.gov/pubmed/34624757
http://dx.doi.org/10.1016/j.breast.2021.09.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503662/
https://www.ncbi.nlm.nih.gov/pubmed/34624757
http://dx.doi.org/10.1016/j.breast.2021.09.012

Ejemplares similares